久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國Nodality  
nodality是一種創新的個性化的醫藥公司，專注于改善療法的藥物開發的效率，以及產生高度預測的同伴診斷，以改善病人護理。單細胞網絡分析（SCNP，single cell network profiling）技術

Nodality is an innovative personalized medicine company focused on improving the efficiency of drug development for therapeutics as well as generating highly predictive companion diagnostics to improve patient care. Nodality's unique and proprietary technology characterizes cell signaling pathway biology in individual patients with single cell resolution. The technology provides unique insights into disease processes, individual patient variability, in addition to mechanisms of treatment response, resistance and relapse.

Nodality utilizes SCNP in cancer and autoimmune diseases to characterize signaling pathways central to the underlying disease biology and response to therapeutics. Nodality's unique functional analysis approach is intended to not only yield comprehensive clinical management tools that inform decisions in diagnosis, prognosis, treatment selection, and monitoring for disease relapse, but also to support drug development.

Nodality partners with pharmaceutical and biotechnology companies to improve the productivity and efficiency of drug development by using SCNP to provide insight into disease biology and effects of pharmacologic agents. Nodality can help drug developers create competitive advantages by accelerating, optimizing, and de-risking clinical trials, as well as by facilitating companion diagnostic development to best match individual patients with the most appropriate treatments.

Only SCNP can provide network-level views of drug and target interactions in cells of interest, including rare cells such as cancer stem cells. The ability to study functional status at baseline and after modulation with a factor such as a new drug candidate allows elucidation of network dynamics not seen with traditional genomic or proteomic technologies. SCNP has successfully profiled the function of cells from blood, bone marrow, and tumor tissue. This approach has been used characterize individual disease biology in hematologic malignancies, autoimmune diseases, and solid tumors.

SCNP was developed in the laboratory of Professor Garry Nolan and licensed from Stanford University. Nodality's investors include Kleiner Perkins Caufield and Byers, Maverick Capital, TPG Ventures, and Pfizer Venture Investments.